Is the need for medications with calming effects ever going to disappear?

Australian and New Zealand Journal of Psychiatry

Volumn 47, Issue 10, 2013, Pages 971-

  Starcevic, Vladan ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; MIRTAZAPINE; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE;

ANXIETY DISORDER; AUSTRALIA; CLINICAL OBSERVATION; DISTRESS SYNDROME; DRUG SAFETY; GENERAL PRACTITIONER; GENERALIZED ANXIETY DISORDER; HUMAN; INSOMNIA; LETTER; OFF LABEL DRUG USE; POSTTRAUMATIC STRESS DISORDER; PRESCRIPTION; TRANQUILIZING ACTIVITY; UNSPECIFIED SIDE EFFECT;

ANTI-ANXIETY AGENTS; ANXIETY; ANXIETY DISORDERS; HEALTH SERVICES NEEDS AND DEMAND; HUMANS;

EID: 84884833646     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867413484371     Document Type: Letter

References (6)

1. Bernardy NC, Lund BC, Alexander B, et al. Prescribing trends in veterans with posttraumatic stress disorder. Journal of Clinical Psychiatry. 2012 ; 73: 297-303
2. Berney P, Halperin D, Tango R, Daeniker-Dyer I, et al. A major change of prescribing pattern in absence of adequate evidence: benzodiazepines versus newer antidepressants in anxiety disorders. Psychopharmacology Bulletin. 2008 ; 41: 39-47
3. Monasterio E, McKean A. Quetiapine use: science or clever marketing?. Australian and New Zealand Journal of Psychiatry. 2013 ; 47: 96-97
4. Starcevic V. Benzodiazepines for anxiety disorders: maximising the benefits and minimising the risks. Advances in Psychiatric Treatment. 2012 ; 18: 250-258
5. Stephenson CP, Karanges E, McGregor IS. Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011. Australian and New Zealand Journal of Psychiatry. 2013 ; 47: 74-87
6. Tyrer P. Why benzodiazepines are not going away. Advances in Psychiatric Treatment. 2012 ; 18: 259-262